Adaptive Biotechnologies Corporation(ADPT)

Biotechnology · Seattle, WA

$29.84+1.49 (+5.26%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T13:10:21.781Z.

Stored calculation inputs

Calculation as of: 2026-10-06T13:10:21.781Z.

Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 4,775,712,960
Total debt · period ending 2026-06-30: 410,499,000
Cash · period ending 2026-06-30: 169,873,000
TTM operating income · period ending 2026-06-30: -37,459,000

FMP input reference: 8b4a3eec411172ef5ea6343195523a59a16bbab67eb0b09a3c3cdf82258b1615

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

ADPT EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

ADPT Competitors' EV/EBIT Ratio

ADPT

Adaptive Biotechnologies Corporation

Current

Market Cap

$4.78B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DFTX

Definium Therapeutics, Inc.

vs ADPT

Market Cap

$4.81B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DNTH

Dianthus Therapeutics, Inc.

vs ADPT

Market Cap

$4.92B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BLLN

BillionToOne, Inc.

vs ADPT

Market Cap

$5.02B

EV/EBIT Ratio

106.50x

TTM Avg

157.20x

3Y Avg

157.20x

5Y Avg

157.20x

HTFL

Heartflow, Inc. Common Stock

vs ADPT

Market Cap

$4.50B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INDV

Indivior Pharmaceuticals Inc

vs ADPT

Market Cap

$4.49B

EV/EBIT Ratio

9.22x

TTM Avg

11.90x

3Y Avg

40.42x

5Y Avg

37.42x

ERAS

Erasca, Inc.

vs ADPT

Market Cap

$5.11B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SRRK

Scholar Rock Holding Corporation

vs ADPT

Market Cap

$5.20B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MMSI

Merit Medical Systems, Inc.

vs ADPT

Market Cap

$5.20B

EV/EBIT Ratio

27.69x

TTM Avg

27.45x

3Y Avg

34.84x

5Y Avg

44.16x

EWTX

Edgewise Therapeutics, Inc.

vs ADPT

Market Cap

$4.34B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Adaptive Biotechnologies Corporation (ADPT)	$4.78B	N/A	N/A	N/A	N/A
Definium Therapeutics, Inc. (DFTX)vs ›	$4.81B	N/A	N/A	N/A	N/A
Dianthus Therapeutics, Inc. (DNTH)vs ›	$4.92B	N/A	N/A	N/A	N/A
BillionToOne, Inc. (BLLN)vs ›	$5.02B	106.50x	157.20x	157.20x	157.20x
Heartflow, Inc. Common Stock (HTFL)vs ›	$4.50B	N/A	N/A	N/A	N/A
Indivior Pharmaceuticals Inc (INDV)vs ›	$4.49B	9.22x	11.90x	40.42x	37.42x
Erasca, Inc. (ERAS)vs ›	$5.11B	N/A	N/A	N/A	N/A
Scholar Rock Holding Corporation (SRRK)vs ›	$5.20B	N/A	N/A	N/A	N/A
Merit Medical Systems, Inc. (MMSI)vs ›	$5.20B	27.69x	27.45x	34.84x	44.16x
Edgewise Therapeutics, Inc. (EWTX)vs ›	$4.34B	N/A	N/A	N/A	N/A

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

About Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers. Another specialized offering, immunoSEQ T-MAP COVID, aids vaccine developers and researchers in quantifying T-cell immune responses to vaccines. Beyond its current product lineup, Adaptive Biotechnologies actively develops a pipeline of clinical products and services designed for the diagnosis, monitoring, and treatment of conditions such as cancer, autoimmune disorders, and infectious diseases. Its solutions cater to life science research, clinical diagnostics, and drug discovery applications. The company has established key strategic collaborations: one with Genentech, Inc., for the joint development, manufacturing, and commercialization of neoantigen-directed T-cell therapies aimed at treating various cancers; and another with Microsoft Corporation, dedicated to creating sophisticated diagnostic tests capable of identifying multiple diseases early from a single blood sample.

Seattle, WA

624 employees

www.adaptivebiotech.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Chad Robins

View full financials

EV/EBIT Ratio: N/A

ADPT EV/EBIT Ratio Metrics

ADPT Competitors' EV/EBIT Ratio

EV/EBIT Ratio Formula & Definition

Related Metrics

EV/EBIT Ratio: N/A

ADPT EV/EBIT Ratio Metrics

ADPT Competitors' EV/EBIT Ratio

EV/EBIT Ratio Formula & Definition

Related Metrics